Sandra sat in her doctor's office in Malta with her arms folded — not defensively, she would later say, but protectively. She had been down this road before.
Last reviewed by the Carisma Medical Team — 2026
Sandra sat in her doctor's office in Malta with her arms folded — not defensively, she would later say, but protectively. She had been down this road before. Shakes, points, meal replacement programmes, a gym membership she used faithfully for four months before the school schedule collapsed around her. She had come today because her sister wouldn't stop mentioning these injections she'd read about. She expected to be handed a leaflet and sent home with a new kind of hope she didn't quite believe in.
Instead, her doctor explained how GLP-1 weight loss injections work in Malta — not as a shortcut, and not as magic, but as something far more interesting: a tool that works with hormones her body was already producing, amplifying a signal that, for many women, has simply been too quiet to make a real difference.
She didn't feel sold to. She felt informed.
That conversation changed how she thought about her weight — not as a personal failure, but as a biological problem that finally had a biological solution worth exploring.
Key Takeaways - GLP-1 injections mimic a natural gut hormone to reduce hunger and improve satiety - They work via four mechanisms: slower digestion, appetite suppression, better insulin sensitivity, and steadier blood sugar - Semaglutide and tirzepatide are the two main clinically supervised options available in Malta - Results typically build over weeks four to sixteen as doses gradually increase - Results may vary — a free medical consultation is the right first step to assess your individual fit
What Is a GLP-1 and Why Does It Matter for Weight Loss?
The hormone your gut already produces
GLP-1 stands for glucagon-like peptide-1. It is not a foreign chemical — it is a hormone your own gut produces every time you eat. Specialised cells in the lining of your small intestine, called L-cells, release GLP-1 in response to food. Once released, it travels to several locations in your body: your pancreas, your stomach, and your brain.
In the pancreas, GLP-1 tells your beta cells to release insulin in proportion to how much glucose is in your bloodstream — which is useful for managing blood sugar after meals. In the stomach, it slows down how quickly food moves through — giving your body more time to register that you have eaten. And in the brain, particularly in the hypothalamus (the region responsible for regulating appetite and hunger), GLP-1 sends a clear signal: you have had enough.
GLP-1 receptor agonist medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — work by mimicking and amplifying this hormone. They bind to the same GLP-1 receptors your natural hormone uses, but they are designed to last much longer in the body. Where your natural GLP-1 breaks down within minutes, these medications remain active for days, providing a sustained, consistent signal that the body is satisfied.
This is the science of understanding how GLP-1 weight loss injections work in Malta and beyond — and it is a meaningful distinction from appetite suppressants that work through willpower or calorie restriction alone.
Why some people have a blunted GLP-1 response
Not everyone's GLP-1 system functions at the same level of sensitivity. Research suggests that some individuals — particularly those who have struggled with weight over many years — may have a reduced postprandial GLP-1 response or reduced receptor sensitivity. In practical terms: your gut is producing the signal, but the system that is supposed to hear it has become quieter. GLP-1 medications effectively turn the volume back up.
This is why understanding the mechanism matters. When the biology is explained clearly, many women say the same thing Sandra said: "So it isn't that I have no self-control. It's that my satiety signals weren't working the way they should." That reframe is often the beginning of a genuine change.
The Four Ways GLP-1 Injections Work in Your Body
Slowing gastric emptying
One of the first things GLP-1 receptor agonists do is slow down how quickly your stomach empties its contents into the small intestine. Normally, food moves through your stomach within one to three hours. On a GLP-1 medication, that process is extended — which means you feel physically full for longer after each meal. You eat less at the next sitting not because you are restricting yourself, but because your stomach is still doing its job from the meal before.
This is particularly relevant for women who describe eating an appropriate meal and feeling hungry again within an hour or two. That pattern is often related to rapid gastric emptying — and GLP-1 medications address it directly.
Reducing appetite signals in the brain
The hypothalamus controls hunger. GLP-1 receptors in its arcuate nucleus — a cluster of neurons that receive signals about food intake, energy balance, and satiety — are directly activated by GLP-1 receptor agonists. The practical effect is that the constant background noise of hunger becomes quieter. Not silenced — most women on these medications still feel appropriate hunger at mealtimes — but the intrusive, persistent urge to eat between meals, or to eat more than the body needs, decreases meaningfully.
Women in clinical programmes often describe it as "food just stops being on my mind all the time." That is not a placebo effect. It is a measurable change in hypothalamic signalling. This appetite suppression is one of the most significant reasons why GLP-1-based programmes achieve outcomes that calorie restriction alone rarely sustains.
Improving insulin sensitivity
GLP-1 receptor agonists stimulate insulin secretion from the pancreas in a way that is specifically linked to glucose levels in the bloodstream — meaning insulin is released when blood sugar is actually elevated, and not otherwise. At the same time, they suppress glucagon, the hormone that raises blood sugar between meals. The combined effect is better glycaemic control and improved insulin sensitivity over time.
For women who have been gaining weight despite eating reasonably — a pattern often connected to insulin resistance — this is significant. Improving how efficiently the body handles glucose is part of why GLP-1-based programmes produce more sustained results than simple calorie restriction.
Lowering post-meal blood sugar spikes
Sharp spikes in blood sugar after meals — followed by rapid drops — are associated with increased hunger, cravings for sugar and refined carbohydrates, and energy crashes. By slowing gastric emptying and improving insulin sensitivity simultaneously, GLP-1 medications smooth out this curve. Meals produce a gentler, more sustained rise and fall in blood glucose rather than a spike and crash. This creates more stable energy throughout the day — which many women notice before they notice any change on the scale.
GLP-1 Medications Available in Malta
Semaglutide (Ozempic, Wegovy)
Semaglutide is a once-weekly GLP-1 receptor agonist. Ozempic (at doses up to 1mg) was originally approved for type 2 diabetes management. Wegovy (semaglutide 2.4mg) is the higher-dose formulation specifically licensed for chronic weight management in adults with obesity or overweight with a weight-related health condition.
In the STEP-1 trial — a large-scale randomised controlled trial published in the New England Journal of Medicine — semaglutide 2.4mg once weekly produced a mean body weight reduction of 14.9% at 68 weeks compared to 2.4% with placebo. 86.4% of participants achieved at least 5% weight loss, and 69.1% achieved at least 10% — outcomes that far exceed what has historically been achievable with lifestyle intervention alone. (Wilding JPH et al., NEJM 2021.)
Results may vary for each individual depending on starting weight, metabolic history, and adherence to lifestyle guidance provided alongside the medication.
Tirzepatide (Mounjaro) — dual GIP and GLP-1
Tirzepatide, marketed as Mounjaro, represents the next generation of this medication class. It is a dual GIP and GLP-1 receptor agonist — a single synthetic molecule that activates two incretin receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) receptors are found not only in the pancreas but in adipose tissue and the central nervous system. The dual activation appears to produce additive or synergistic effects on appetite suppression and fat metabolism beyond what GLP-1 alone achieves.
In the SURMOUNT-1 trial — a 72-week randomised controlled trial published in the New England Journal of Medicine — tirzepatide produced mean body weight reductions of 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg, compared to 3.1% with placebo. At the highest dose, 56.7% of participants achieved at least 20% weight loss — a threshold previously unachievable with any approved anti-obesity medicine. (Jastreboff AM et al., NEJM 2022.) The EMA granted approval for tirzepatide for chronic weight management in November 2023.
Our clinically supervised GLP-1 programme at Carisma Slimming helps you understand which medication is appropriate for your individual clinical profile. You can learn more about our GLP-1 Medical Weight Loss Programme here.
How Long Before You Feel the Effects?
Week 1–4: what most people notice
The first weeks on a GLP-1 medication are a period of biological adjustment, not dramatic transformation. Most women notice a reduction in appetite — sometimes subtle, sometimes quite pronounced — within the first week or two. Food thoughts become less intrusive. Portions feel satisfying at a smaller size. The need to snack between meals decreases.
What many people also notice in weeks one to four are some gastrointestinal side effects: nausea, particularly after the first few doses, and occasionally loose stools or constipation. These effects are well-documented in clinical trials — nausea was reported in approximately 40-45% of participants at the highest tirzepatide dose in SURMOUNT-1, though it typically peaks in the first four to eight weeks of each dose escalation and then subsides. Managing meals carefully during this period — smaller portions, lower-fat foods, staying upright after eating — helps significantly.
Weight loss in weeks one to four is typically modest: often 0.5 to 1.5 kilograms, reflecting the fact that the dose is still at its starting level and the body is still adapting.
Dose escalation and why it is gradual
GLP-1 medications are started at a low dose and increased incrementally every four weeks. This is not a delay tactic — it is intentional medical design. The slow titration serves two purposes: it allows the body to adapt to the medication's effects on gastric motility (reducing side effects), and it means the therapeutic effect builds progressively over time as the dose approaches its target level.
The most rapid phase of weight loss typically occurs between weeks four and sixteen, as dose escalation progresses. Results continue, more gradually, through weeks sixteen to thirty-six and beyond. This is why a short-term trial of a GLP-1 medication does not reflect its full potential — and why clinically supervised, structured programmes with adequate duration are important for meaningful outcomes.
What GLP-1 Injections Do Not Do
They are not a metabolism booster
GLP-1 receptor agonists do not raise your resting metabolic rate or cause your body to burn more calories at rest. The primary mechanism of action is appetite suppression and improved glucose handling — the result is that you consume fewer calories because you are genuinely less hungry, not because your metabolic rate has sped up. This distinction matters because it shapes what realistic expectations should look like.
Why diet and activity still matter
The clinical trials that produced the weight loss figures cited above were conducted with participants who also received dietary counselling and guidance on physical activity. In STEP-3 (Wadden TA et al., NEJM 2021) — where semaglutide was combined with intensive behavioural intervention — the mean weight loss reached 16.0%. Medication amplifies the effect of lifestyle changes; it does not replace them.
At Carisma Slimming, our clinically supervised programme includes nutritional guidance alongside the medication itself. Specifically, adequate protein intake — 1.2 to 1.6 grams per kilogram of body weight per day, consistent with ESPEN clinical guidelines — is a key focus during GLP-1-assisted weight loss. This matters because when total caloric intake drops significantly, lean muscle mass can account for 25 to 40% of total weight lost if protein intake is not actively prioritised. Preserving muscle protects your metabolism and your long-term results.
A Mediterranean-style eating pattern is particularly well-aligned with GLP-1 treatment — high in vegetables, legumes, olive oil, fish, and wholegrains, with minimal ultra-processed foods that can override GLP-1-mediated satiety through hedonic eating pathways. For Malta specifically, this is also a culturally familiar framework, not a foreign prescription.
If you are considering complementary body contouring treatments alongside a GLP-1 programme, you can explore our full range of slimming packages designed to support your overall progress.
The Role of Medical Supervision While on GLP-1s in Malta
GLP-1 medications are prescription treatments. They are not supplements, and they are not appropriate for everyone. Medically supervised oversight throughout the programme is not optional — it is what makes the difference between a medication taken and a medication that works safely and sustainably.
At Carisma Slimming, the process begins with a full clinical assessment before any medication is considered. This includes reviewing your medical history, current medications, and relevant health markers. GLP-1 receptor agonists are contraindicated in certain situations — including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, current pregnancy or breastfeeding, and severe gastrointestinal disease. These are not bureaucratic boxes to tick; they are the reason why an online order and self-management cannot replicate what a proper clinical programme provides.
Ongoing monitoring throughout the programme includes dose titration decisions based on your tolerance and progress, management of any side effects, nutritional review, and periodic check-ins to assess how your body is responding. When something isn't working as expected — a plateau, a side effect that doesn't ease, a change in circumstances — your clinical team adapts the plan accordingly.
The results you hear about from these medications happen within clinically supervised programmes. That context is not incidental. It is the mechanism.
Is a GLP-1 Programme Right for You?
The clinical eligibility criteria for GLP-1 medications, per EMA-approved guidelines, are a BMI of 30 kg/m² or higher (classified as obesity), or a BMI of 27 kg/m² or higher with at least one weight-related health condition — such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, or cardiovascular disease.
But eligibility is only the starting point. The fuller question is whether this approach fits your life, your health history, and your goals.
If you are a busy parent who has tried calorie-counting and found it unsustainable under the demands of family life — a GLP-1 programme addresses the biological underpinning of hunger rather than relying on willpower alone.
If you are a woman in perimenopause or menopause who has found that approaches that worked in your thirties no longer produce results — the insulin-sensitivity and appetite-regulation mechanisms of GLP-1 medications are particularly relevant to the hormonal shifts of this life stage.
If you have significant weight to lose and have felt overwhelmed by the scale of the task — a clinically supervised programme with staged, supported progress is a structurally different approach to anything you may have tried independently.
A consultation is the right first step. It costs nothing, and it gives you personalised information rather than general guidance. Book your free consultation at Carisma Slimming to find out whether a GLP-1 programme is appropriate for your individual situation.
Results may vary for each individual based on starting weight, metabolic profile, programme adherence, and other health factors. A consultation is the starting point for understanding what your specific journey might look like.
FAQs About GLP-1 Injections in Malta
Do GLP-1 injections work without changing your diet?
The clinical trials that demonstrated significant weight loss — including STEP-1 (semaglutide, 14.9% mean weight loss at 68 weeks) and SURMOUNT-1 (tirzepatide, up to 20.9% at 72 weeks) — included dietary counselling alongside the medication. GLP-1 injections reduce hunger and improve satiety, which naturally leads most people to eat less. But actively prioritising protein, reducing ultra-processed foods, and following nutritional guidance from your clinical team amplifies outcomes significantly. The medication creates the conditions for change; what you eat within those conditions still matters meaningfully.
How quickly do GLP-1 injections start working?
Most women notice a reduction in appetite and food preoccupation within the first one to two weeks, even at the starting dose. Measurable weight changes are typically modest in the first four weeks — often 0.5 to 1.5 kilograms — as the dose is still in its initial escalation phase. The most significant weight loss phase typically occurs between weeks four and sixteen as the dose builds toward its therapeutic target. The full effect of a GLP-1 programme takes months, not weeks, which is why clinically supervised programmes of adequate duration produce the results seen in clinical trials.
Are GLP-1 injections the same as insulin injections?
No — and this is a common source of confusion worth clearing up. Insulin is a hormone that directly lowers blood sugar and is used to treat diabetes. GLP-1 receptor agonists are a completely different class of medication. They mimic a gut hormone that regulates appetite and supports blood sugar control in a glucose-dependent way — meaning they only stimulate insulin release when blood sugar is actually elevated. They are given as a once-weekly subcutaneous injection (just under the skin, typically in the abdomen, thigh, or upper arm), but the mechanism and purpose are entirely different from insulin therapy.
Can GLP-1 injections cause low blood sugar (hypoglycaemia)?
In people without type 2 diabetes who are not taking other glucose-lowering medications, GLP-1 receptor agonists carry a very low risk of hypoglycaemia. This is because they stimulate insulin release in a glucose-dependent manner — when blood sugar is high after eating, and not when levels are already normal or low. The risk profile is different for individuals who are also taking other diabetes medications such as sulphonylureas. This is one of many reasons why a full medical review before starting any GLP-1 programme is non-negotiable, and why our clinically supervised approach at Carisma Slimming includes a thorough clinical assessment from the outset.
Do you inject GLP-1 yourself at home?
Yes, in most cases. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) come in pre-filled, single-use auto-injector pens designed for self-administration. They are given once weekly as a small subcutaneous injection. The injectors are designed to be simple and virtually painless — the needle is very fine and very short. Your clinical team will walk you through the process at your first prescription appointment and provide clear guidance on technique and aftercare.
What is the difference between GLP-1 and GIP in Mounjaro?
Mounjaro (tirzepatide) is a dual-receptor agonist: it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP receptors are found not only in the pancreas but in fat tissue and the brain. The dual activation produces additive or synergistic effects on appetite suppression and fat metabolism beyond what GLP-1 receptor activation alone achieves. The SURMOUNT-5 trial (2025, published in the New England Journal of Medicine) directly compared tirzepatide against semaglutide 2.4mg and found approximately 47% greater weight loss with tirzepatide at 72 weeks. Whether semaglutide or tirzepatide is right for a specific individual depends on clinical factors, tolerability, and medical history — your healthcare provider will guide that decision.
You Don't Have to Figure This Out Alone
Understanding the biology behind GLP-1 injections can feel like the first exhale in a very long breath-hold. Not because it promises everything — it doesn't — but because it explains something real about why previous approaches fell short. Your hunger was not a character flaw. Your metabolism was not broken. There were biological forces at work that a calorie-counting app was never designed to address.
GLP-1 medications, in a clinically supervised programme with proper clinical oversight, nutritional guidance, and ongoing support, offer something structurally different from what most women in Malta have had access to until now.
You deserve support that actually fits your body, your life stage, and your history. Not a plan built for a hypothetical person with infinite time and simple hormones. A plan built around you.
Book your free consultation at Carisma Slimming. Our clinical team in Malta will walk through your individual situation — your health history, your goals, your questions — and give you clear, honest guidance on whether a GLP-1 programme is the right fit. No pressure. No obligation. Just information you can actually use.
Picture yourself twelve weeks from now: climbing stairs without thinking about it, sleeping more deeply, carrying your shopping from the car without stopping to rest, sitting down to a meal and feeling satisfied rather than still searching for something. That picture is possible. And it starts with one conversation.
With you every step, Katya
FAQ Schema (Structured Data)
Q: Do GLP-1 injections work without changing your diet? A: The clinical trials that demonstrated significant weight loss — including STEP-1 (semaglutide, 14.9% mean weight loss at 68 weeks) and SURMOUNT-1 (tirzepatide, up to 20.9% at 72 weeks) — included dietary counselling alongside the medication. GLP-1 injections reduce hunger and improve satiety, which naturally leads most people to eat less. But actively prioritising protein, reducing ultra-processed foods, and following nutritional guidance from your clinical team amplifies outcomes significantly. The medication creates the conditions for change; what you eat within those conditions still matters meaningfully.
Q: How quickly do GLP-1 injections start working? A: Most women notice a reduction in appetite and food preoccupation within the first one to two weeks, even at the starting dose. Measurable weight changes are typically modest in the first four weeks — often 0.5 to 1.5 kilograms — as the dose is still in its initial escalation phase. The most significant weight loss phase typically occurs between weeks four and sixteen as the dose builds toward its therapeutic target. The full effect of a GLP-1 programme takes months, not weeks, which is why clinically supervised programmes of adequate duration produce the results seen in clinical trials.
Q: Are GLP-1 injections the same as insulin injections? A: No — and this is a common source of confusion worth clearing up. Insulin is a hormone that directly lowers blood sugar and is used to treat diabetes. GLP-1 receptor agonists are a completely different class of medication. They mimic a gut hormone that regulates appetite and supports blood sugar control in a glucose-dependent way — meaning they only stimulate insulin release when blood sugar is actually elevated. They are given as a once-weekly subcutaneous injection, but the mechanism and purpose are entirely different from insulin therapy.
Q: Can GLP-1 injections cause low blood sugar (hypoglycaemia)? A: In people without type 2 diabetes who are not taking other glucose-lowering medications, GLP-1 receptor agonists carry a very low risk of hypoglycaemia. This is because they stimulate insulin release in a glucose-dependent manner — when blood sugar is high after eating, and not when levels are already normal or low. The risk profile is different for individuals also taking other diabetes medications such as sulphonylureas. This is one of many reasons why a full medical review before starting any GLP-1 programme is non-negotiable, and why our clinically supervised approach at Carisma Slimming includes a thorough clinical assessment from the outset.
Q: Do you inject GLP-1 yourself at home? A: Yes, in most cases. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) come in pre-filled, single-use auto-injector pens designed for self-administration. They are given once weekly as a small subcutaneous injection. The injectors are designed to be simple and virtually painless — the needle is very fine and very short. Your clinical team will walk you through the process at your first prescription appointment and provide clear guidance on technique and aftercare.
Q: What is the difference between GLP-1 and GIP in Mounjaro? A: Mounjaro (tirzepatide) is a dual-receptor agonist: it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP receptors are found not only in the pancreas but in fat tissue and the brain. The dual activation produces additive or synergistic effects on appetite suppression and fat metabolism beyond what GLP-1 receptor activation alone achieves. The SURMOUNT-5 trial (2025, NEJM) found approximately 47% greater weight loss with tirzepatide versus semaglutide at 72 weeks. Whether semaglutide or tirzepatide is appropriate depends on clinical factors, tolerability, and medical history — your healthcare provider will guide that decision.
Internal Links Placed
our GLP-1 Medical Weight Loss Programme here • Book your free consultation at Carisma Slimming (×2) • slimming packages
CTA
Book your free consultation at Carisma Slimming today. Our clinical team in Malta will walk through your individual situation — your health history, your goals, your questions — and give you clear, honest guidance on whether a GLP-1 programme is the right fit. No pressure. No obligation. Just information you can actually use. Picture yourself twelve weeks from now: climbing stairs without thinking about it, sleeping more deeply, carrying your shopping from the car without stopping to rest. That picture is possible. And it starts with one conversation. With you every step, Katya
Image Credits
Hero Image URL: https://images.pexels.com/photos/7659873/pexels-photo-7659873.jpeg?auto=compress&cs=tinysrgb&h=650&w=940 • Photographer: Thirdman • Pexels Page: https://www.pexels.com/photo/doctor-consulting-a-patient-7659873/ • Alt text: How do GLP-1 weight loss injections work Malta — female doctor consulting a smiling patient in a welcoming clinical setting • Caption: A doctor-led consultation is the first step to understanding whether GLP-1 weight loss injections are right for you. • Filename: glp1-injections-doctor-consultation.jpg • Query used: doctor patient consultation wellness
Inline Image URL: https://images.pexels.com/photos/6739121/pexels-photo-6739121.jpeg?auto=compress&cs=tinysrgb&h=650&w=940 • Photographer: Mikhail Nilov • Alt text: Confident woman in casual attire standing indoors with natural light, reflecting a healthy lifestyle • Query used: woman healthy lifestyle wellness confidence
QC Report
Score: 95/100 | Status: APPROVED
validationOpening: pass • primaryKeywordInH1: pass • minimumWordCount1700: pass • resultsVaryPresent: pass • medicallySupervisedPresent: pass • minimum5FAQs: pass • minimum2InternalLinks: pass • consultationLinkPresent: pass • fearFAQPresent: pass • zeroShameLanguage: pass • nonScaleWinsPresent: pass • minimum2CredibleSources: pass • maltaMentioned: pass • ymylSafe: pass
More from the blog
